Medical Marijuana ProCon.org HOME | CLOSE

1. Name: Camille B. Carroll, Ph.D., MRCP
2. Title: Department of Neurology, Derriford Hospital, Plymouth, United Kingdom
3. Medical Marijuana
Position:		 No position found to the question "Should marijuana be a medical option?"
4. Reasoning:

"Seventeen patients completed the RCT (randomized placebo-controlled crossover study). Cannabis was well tolerated, and had no pro- or antiparkinsonian action. There was no evidence for a treatment effect on levodopa-induced dyskinesia as assessed by the UPDRS, or any of the secondary outcome measures.

Conclusions: Orally administered cannabis extract resulted in no objective or subjective improvement in dyskinesias or parkinsonism." ("Cannabis For Dyskinesia In Parkinson Disease: A Randomized Double-blind Crossover Study," Neurology 2004)

5. Credibility
Ranking:

 Experts
PhD's and JD's (lawyers) with significant post-doctoral involvement in medical marijuana issues; judges who have presided over medical marijuana cases.

6. Involvement:
  • Department of Neurology, Derriford Hospital
7. Education:
  • Ph.D, school unknown
8. Relevant Affiliations/Honors:
  • Member of the Royal College of Physicians (MRCP)
9. Contact Info:
Phone:  0845 155 8155, Main Office Fax:  0845 155 8235, Main Office
E-Mail:   camille.carroll@pms.ac.uk
Web Site: Derriford Hospital Website
10. Other: Select Publications:
  • Co-author "Cannabis For Dyskinesia In Parkinson Disease: A Randomized Double-blind Crossover Study," Neurology 2004, 63: 1245-50
  • Co-author "The Effect of Cannabis on Tremor Patients with Multiple Sclerosis," Neurology 2004, 62: 1105-1109
HOME | CLOSE